IMMUNITYBIO INC (IBRX) Stock News
NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD
IBRX Latest News, Press Relases and Analysis
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
Gossamer Bio, Inc. (GOSS): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Nuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where Intellia Therapeutics, Inc. (NASDAQ:NTLA) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the […]
ImmunityBio, Inc. (IBRX): Among Stocks Under $10 that Will Triple
We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ImmunityBio, Inc. (NASDAQ:IBRX) stands against other stocks under $10 that will triple. As we delve into the discussion on stocks that will triple, we must shed light on the U.S. […]
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday?
We recently published a list of Tuesday’s 10 Worst-Performing Stocks. In this article, we are going to take a look at where ImmunityBio Inc. (NASDAQ:IBRX) stands against other Tuesday’s worst-performing stocks. Wall Street’s main indices suffered a bloodbath on Tuesday, recording steep losses amid the looming deadline for President Donald Trump’s new round of tariffs […]
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities
/PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC. SECURITIES LITIGATION No. 3:23-cv-01216-GPC-VET NOTICE OF...
ImmunityBio to Host Investor Day
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
The company said that Merck’s TICE BCG shortages have created a significant hurdle for bladder cancer treatment.
Mentions: MRK
FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
ImmunityBio Stock Soars On BeiGene Tie-Up, Supply Deal: Retail Gets Dose Of Optimism
The study will evaluate a combination therapy using BeiGene’s tislelizumab and ImmunityBio’s Anktiva for certain patients with advanced or metastatic non-small cell lung cancer
Mentions: ONC
ImmunityBio Stock Trading Higher On Updates From Bladder Cancer Trials: Details
On Wednesday, ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical development pipeline in non-muscle invasive bladder cancer (NMIBC) and non-small cell lung cancer (NSCLC). NMIBC BCG Unresponsive Papillary Disease: ImmunityBio is preparing to submit a supplemental Biologics License Application (sBLA) in 2025 for its treatment targeting Bacillus Calmette-Guérin (BCG) unresponsive NMIBC in the papillary indication. As published in
ImmunityBio Provides Regulatory Update on Anticipated FDA Submissions in 2025 Following Meeting with the Agency
